Literature DB >> 28866292

The road to a more effective influenza vaccine: Up to date studies and future prospects.

Kaori Sano1, Akira Ainai1, Tadaki Suzuki1, Hideki Hasegawa2.   

Abstract

Influenza virus causes an acute respiratory infection in humans. Frequent point mutations in the influenza genome and occasional exchange of genetic segments between virus strains help the virus evade the pre-existing immunity, resulting in epidemics and pandemics. Although vaccination is the most effective intervention, mismatches between circulating viruses and vaccine strains reduce vaccine efficacy. Furthermore, current injectable vaccines induce IgG antibodies in serum (which limit progression of influenza symptoms) but not secretory IgA antibodies in the respiratory mucosa (which prevent virus infection efficiently). Therefore, numerous studies have attempted to improve influenza vaccines. The discovery of broadly neutralizing antibodies has progressed research into antigen design. Studies designed to improve vaccine efficacy by changing the vaccine administration route have also been conducted. A thorough understanding of the mechanisms underlying the action of various vaccines is essential if we are to develop a universal influenza vaccine. Therefore, evaluating the quality and quantity of antibodies induced by vaccines, which determine vaccine efficacy, is critical. However, at present vaccine evaluation relies on hemagglutination inhibition tests, which only measure the quantity of antibody produced. Antibody repertoires comprise a set of antibodies with specific genetic or molecular features that correspond to their functions. Genetically and functionally similar antibodies may be produced by multiple individuals exposed to an identical stimulus. Therefore, it may be possible to evaluate and compare multiple vaccine strategies in terms of the quality and quantity of an antibody response induced by a vaccine by examining antibody repertoires. Recent studies have used single cell expression and high-throughput immunoglobulin sequencing to provide a detailed picture of antibody responses. These novel methods may be critical for detailed characterization of antibody repertoires induced by various vaccination strategies.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody response repertoires; Broadly neutralizing antibody; Influenza; Influenza vaccine; Intranasal inactivated influenza vaccine

Mesh:

Substances:

Year:  2017        PMID: 28866292     DOI: 10.1016/j.vaccine.2017.08.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Influenza Vaccines: Good, but We Can Do Better.

Authors:  Catharine I Paules; Anthony S Fauci
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

2.  Structural and functional definition of a vulnerable site on the hemagglutinin of highly pathogenic avian influenza A virus H5N1.

Authors:  Pengfei Wang; Yanan Zuo; Jianfeng Sun; Teng Zuo; Senyan Zhang; Shichun Guo; Xuanling Shi; Mifang Liang; Paul Zhou; Linqi Zhang; Xinquan Wang
Journal:  J Biol Chem       Date:  2019-02-08       Impact factor: 5.157

Review 3.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

Review 4.  Factors influencing the immunogenicity of influenza vaccines.

Authors:  Simin Wen; Zhengyu Wu; Shuyi Zhong; Mao Li; Yuelong Shu
Journal:  Hum Vaccin Immunother       Date:  2021-03-11       Impact factor: 3.452

5.  Regional differences in general practitioners' behaviours regarding influenza vaccination: a cross-sectional study.

Authors:  Jonathan Arlt; Kristina Flaegel; Katja Goetz; Jost Steinhaeuser
Journal:  BMC Health Serv Res       Date:  2021-03-04       Impact factor: 2.655

Review 6.  Influenza Virus and SARS-CoV-2 Vaccines.

Authors:  Adam M Sandor; Michael S Sturdivant; Jenny P Y Ting
Journal:  J Immunol       Date:  2021-05-21       Impact factor: 5.426

7.  Development and Regulation of Novel Influenza Virus Vaccines: A United States Young Scientist Perspective.

Authors:  Surender Khurana
Journal:  Vaccines (Basel)       Date:  2018-04-27

Review 8.  Insights From Analysis of Human Antigen-Specific Memory B Cell Repertoires.

Authors:  Hemangi B Shah; Kenneth Smith; Jonathan D Wren; Carol F Webb; Jimmy D Ballard; Rebecka L Bourn; Judith A James; Mark L Lang
Journal:  Front Immunol       Date:  2019-01-15       Impact factor: 7.561

Review 9.  Adult Immunization - Need of the Hour.

Authors:  Abhishek Jairaj; P Shirisha; Muqthadir Siddiqui Mohammad Abdul; Urooj Fatima; Rahul Vinay Chandra Tiwari; Muhamood Moothedath
Journal:  J Int Soc Prev Community Dent       Date:  2018-11-29

10.  IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody.

Authors:  Shinji Saito; Kaori Sano; Tadaki Suzuki; Akira Ainai; Yuki Taga; Tomonori Ueno; Koshiro Tabata; Kumpei Saito; Yuji Wada; Yuki Ohara; Haruko Takeyama; Takato Odagiri; Tsutomu Kageyama; Kiyoko Ogawa-Goto; Pretty Multihartina; Vivi Setiawaty; Krisna Nur Andriana Pangesti; Hideki Hasegawa
Journal:  PLoS Pathog       Date:  2019-01-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.